Here, Steeland et al. (2018) showed that therapeutic blockage of TNFR1 by TROS prevented the cognitive decline in APP/PS1tg/wt mice and upon icv AβO injection, outlining the therapeutic potential of TNFR1 antagonists for AD. Here, APP is linked to Alzheimer disease.